Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
54.63 -2.05 (-3.62%) 03/28/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 58.63 +4.00 (+7.32%) 18:41 ET
Profile for Fri, Mar 28th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Corcept Therapeutics 101 REDWOOD SHORES PARKWAY REDWOOD CITY CA 94065 USA

www.corcept.com Employees: 500 P: 650-688-8803

Sector:

Medical

Description:

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone), is approved for the once-daily oral treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, suffering from type II diabetes or glucose intolerance and who have failed surgery or are not suitable for surgery.

Key Statistics

Overview:

Market Capitalization, $K 5,763,629
Enterprise Value, $K 5,635,959
Shares Outstanding, K 105,503
Annual Sales, $ 675,040 K
Annual Net Income, $ 141,210 K
Last Quarter Sales, $ 181,890 K
Last Quarter Net Income, $ 30,750 K
EBIT, $ 136,950 K
EBITDA, $ 127,350 K
60-Month Beta 0.61
% of Insider Shareholders 20.50%
% of Institutional Shareholders 93.61%
Float, K 83,875
% Float 79.50%
Short Volume Ratio 0.83

Growth:

1-Year Return 116.87%
3-Year Return 130.99%
5-Year Return 368.93%
5-Year Revenue Growth 120.25%
5-Year Earnings Growth 59.74%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.26 on 02/26/25
Next Earnings Date 05/07/25
Earnings Per Share ttm 1.24
EPS Growth vs. Prev Qtr -36.59%
EPS Growth vs. Prev Year -7.14%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CORT Ratios

Ratio
Price/Earnings ttm 45.71
Price/Earnings forward 30.35
Price/Earnings to Growth N/A
Return-on-Equity % 22.70%
Return-on-Assets % 18.66%
Profit Margin % 20.92%
Debt/Equity 0.00
Price/Sales 8.86
Price/Cash Flow 45.64
Price/Book 8.74
Book Value/Share 6.49
Interest Coverage -1.58
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies